4,478 Shares in Surmodics, Inc. (NASDAQ:SRDX) Bought by SG Americas Securities LLC

SG Americas Securities LLC bought a new position in shares of Surmodics, Inc. (NASDAQ:SRDX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 4,478 shares of the company’s stock, valued at approximately $163,000.

A number of other large investors have also modified their holdings of SRDX. Kennedy Capital Management LLC grew its holdings in shares of Surmodics by 227.7% during the second quarter. Kennedy Capital Management LLC now owns 293,359 shares of the company’s stock worth $9,185,000 after buying an additional 203,832 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in shares of Surmodics during the first quarter worth $4,585,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Surmodics during the first quarter worth $2,650,000. Jane Street Group LLC purchased a new stake in shares of Surmodics during the first quarter worth $2,059,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Surmodics during the first quarter worth $1,763,000. Hedge funds and other institutional investors own 96.63% of the company’s stock.

Surmodics Trading Down 2.1 %

Shares of SRDX opened at $26.42 on Tuesday. The company has a current ratio of 4.84, a quick ratio of 3.97 and a debt-to-equity ratio of 0.24. Surmodics, Inc. has a 12-month low of $16.79 and a 12-month high of $39.41. The firm has a 50-day moving average price of $29.82 and a 200 day moving average price of $32.00. The firm has a market capitalization of $376.22 million, a P/E ratio of 69.53 and a beta of 1.01.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $47.00 target price on shares of Surmodics in a report on Wednesday, April 10th.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).